Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 8/20 | 0.56 |
| ▸ | CTSL | P07711 | 7/20 | 0.56 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | CTSB | P07858 | 5/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516128 | 1.00 | ATM (0.58) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL4561240 | 1.00 | ATM (0.58) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL19384886 | 0.90 | CTSK (0.58) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL18342578 | 0.90 | CTSK (0.58) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL10611150 | 0.89 | CTSK (0.57) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL10611157 | 0.89 | CTSK (0.57) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL25409985 | 0.86 | ATM (0.57) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL6312473 | 0.86 | CTSS (0.62) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL6311738 | 0.86 | CTSS (0.62) | ATMCTSSCTSLCTSKCTSB | |
| SCHEMBL23810165 | 0.86 | ATM (0.57) | ATMCTSSCTSLCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | claimed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | claimed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | claimed |
| US-5367086-A | Process for the preparation of taxol and 10-deacetyltaxol | UNIVERSITY OF FLORIDA (US) | 1994-11-22 | — | — | US | claimed |
| US-5200534-A | Process for the preparation of taxol and 10-deacetyltaxol | UNIVERSITY OF FLORIDA (US) | 1993-04-06 | — | — | US | claimed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| EP-3310440-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-25 | — | — | EP | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016207089-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-9481709-B2 | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism | OBE THERAPY BIOTECHNOLOGY (FR) | 2016-11-01 | — | — | US | disclosed |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2014-07-03 | — | — | US | disclosed |
| US-20100311690-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2010-12-09 | — | — | US | disclosed |
| US-4665065-A | 3-pyrazolo(1,5-aαpyridinium cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0216385-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1987-04-01 | — | — | EP | disclosed |
| EP-0074761-B1 | PEPTIDE-TYPE SUBSTRATES USEFUL IN THE QUANTITATIVE DETERMINATION OF ENDOTOXIN | WHITTAKER CORPORATION (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0164122-A2 | Cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0164113-A2 | 3-pyrazolo(1,5-a)pyridinium cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
| EP-0160252-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-11-06 | — | — | EP | disclosed |
| EP-0004024-B1 | METHOD FOR PREPARING 3-HYDROXY-6-PHENYL-1,2,3,4-TETRAHYDRO-1,5-BENZODIAZOCINES | Kali-Chemie Pharma GmbH (DE) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311690-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, ANPEP | ATM 4412/4885CTSS 855/4885CTSL 566/4885 |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, FABP4 | ATM 4456/4885CTSS 1134/4885CTSL 570/4885 |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | ATM 4168/4885CTSS 3166/4885CTSL 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.